Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for Pediatrix Medical (MD) over the last 17 years, with Q3 2025 value amounting to $51.1 million.

  • Pediatrix Medical's Change in Accured Expenses rose 482.95% to $51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$198.5 million, marking a year-over-year decrease of 1304.03%. This contributed to the annual value of $51.1 million for FY2024, which is 27938.82% up from last year.
  • As of Q3 2025, Pediatrix Medical's Change in Accured Expenses stood at $51.1 million, which was up 482.95% from $69.7 million recorded in Q2 2025.
  • Pediatrix Medical's Change in Accured Expenses' 5-year high stood at $85.3 million during Q4 2024, with a 5-year trough of -$159.7 million in Q1 2025.
  • Moreover, its 5-year median value for Change in Accured Expenses was $41.2 million (2023), whereas its average is -$3.1 million.
  • Per our database at Business Quant, Pediatrix Medical's Change in Accured Expenses plummeted by 10321.55% in 2021 and then soared by 218112.09% in 2022.
  • Pediatrix Medical's Change in Accured Expenses (Quarter) stood at -$2.7 million in 2021, then soared by 2181.12% to $56.4 million in 2022, then plummeted by 51.08% to $27.6 million in 2023, then skyrocketed by 208.92% to $85.3 million in 2024, then plummeted by 40.07% to $51.1 million in 2025.
  • Its Change in Accured Expenses was $51.1 million in Q3 2025, compared to $69.7 million in Q2 2025 and -$159.7 million in Q1 2025.